Intra-Articular PRP Versus Dexamethasone for TMJ Internal Derangement
Evaluation of the Efficacy of Intra-Articular Injection of Platelet-Rich Plasma Versus Dexamethasone With Local Anaesthetic in the Treatment of Internal Derangement of the Temporomandibular Joint: A Randomised Controlled Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Al Najaf
-
Ramadi, Al Najaf, Iraq, 54001
- College of Dentistry, University of Anbar
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Inclusion Criteria:
- Skeletally mature patients aged 18 years or older
- Symptomatic TMJ internal derangement in the form of disc displacement with reduction (DDwR), diagnosed using DC/TMD Axis I clinical criteria
- TMJ arthralgia confirmed by pain reproduced on palpation or provoked by jaw movement
- Clicking sound detectable on palpation or auscultation during opening and closing movements
- Elimination or marked reduction of the click on mouth opening from a protruded position
Exclusion Criteria:
- Intra-articular injection within the previous six months
- Systemic inflammatory arthropathy
- Coagulopathy
- Active local infection
- Low platelet count
- Ongoing antiplatelet or anticoagulant therapy
- Pregnancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: PRP
Single intra-articular injection of 0.6 mL leukocyte-poor platelet-rich plasma (PRP) into the superior joint space via a preauricular approach.
|
Autologous platelet-rich plasma (1 mL) prepared from the patient's own venous blood by centrifugation, injected into the superior joint space of the temporomandibular joint under a standardised preauricular approach.
|
|
Active Comparator: Dexamethasone + Local Anaesthetic
Single intra-articular injection of dexamethasone 4 mg (0.5 mL) combined with lidocaine 2% (0.5 mL), total 1 mL, into the superior joint space.
|
Intra-articular injection (1 mL) of dexamethasone combined with a local anaesthetic, delivered into the superior joint space of the temporomandibular joint using the same standardised preauricular approach as the other study arms.
|
|
Placebo Comparator: Normal Saline (Control)
Single intra-articular injection of 1 mL sterile 0.9% sodium chloride into the superior joint space, replicating the full procedural experience without an active agent.
|
Intra-articular injection (1 mL) of normal saline solution into the superior joint space of the temporomandibular joint, serving as the placebo control, using the same standardised preauricular approach as the other study arms.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Pain Intensity (VAS)
Time Frame: Baseline and 1 week post-injection
|
Pain intensity rated on a 10-cm visual analogue scale (0=no pain, 10=worst imaginable pain), reflecting the most intense pain during function.
|
Baseline and 1 week post-injection
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Joint Sound (Clicking)
Time Frame: Baseline and 1 week post-injection
|
Joint sound graded by a blinded assessor on a 3-point ordinal scale: 0=no clicking, 1=clicking detectable on palpation only, 2=clearly audible clicking.
|
Baseline and 1 week post-injection
|
|
Change in Maximum Interincisal Opening (MIO)
Time Frame: Baseline and 1 week post-injection
|
Maximum interincisal opening measured in millimetres between upper and lower central incisors at maximum voluntary mouth opening.
|
Baseline and 1 week post-injection
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Sabah Alheeti, BDS, CABMS, FIBMS, Oral and Maxillofacial Surgery Department / College of Dentistry / University of Anbar
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Musculoskeletal Diseases
- Stomatognathic Diseases
- Muscular Diseases
- Joint Diseases
- Jaw Diseases
- Mandibular Diseases
- Craniomandibular Disorders
- Myofascial Pain Syndromes
- Temporomandibular Joint Disorders
- Temporomandibular Joint Dysfunction Syndrome
- Pharmaceutical Preparations
- Polycyclic Compounds
- Pregnadienes
- Pregnanes
- Steroids
- Fused-Ring Compounds
- Steroids, Fluorinated
- Crystalloid Solutions
- Isotonic Solutions
- Solutions
- Anesthesia and Analgesia
- Pregnadienetriols
- Anesthesia, Conduction
- Anesthesia
- Dexamethasone
- Saline Solution
- Anesthesia, Local
Other Study ID Numbers
Other Study ID Numbers
- UoAnbar-TMJ-PRP-2025
- 141 (Other Identifier: University of Anbar Ethical Approval Committee)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.